n-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide has been researched along with Benign Neoplasms in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 23 (76.67) | 29.6817 |
| 2010's | 5 (16.67) | 24.3611 |
| 2020's | 2 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Cecchi, A; Innocenti, A; Montero, JL; Scozzafava, A; Supuran, CT; Vullo, D; Winum, JY | 1 |
| Cecchi, A; Fasolis, G; Gamberi, A; Montero, JL; Puccetti, L; Scozzafava, A; Supuran, CT; Winum, JY | 1 |
| Brzozowski, Z; Innocenti, A; Kornicka, A; Pomarnacka, E; Saczewski, F; Scozzafava, A; Supuran, CT; Sławiński, J | 1 |
| De Simone, G; Di Fiore, A; Montero, JL; Pedone, C; Scozzafava, A; Supuran, CT; Vitale, RM; Winum, JY | 1 |
| Innocenti, A; Marques, S; Santos, MA; Scozzafava, A; Supuran, CT; Vullo, D | 1 |
| Brzozowski, Z; Innocenti, A; Kornicka, A; Pomarnacka, E; Saczewski, F; Scozzafava, A; Supuran, CT; Sławiński, J; Temperini, C | 1 |
| D'Ambrosio, K; De Simone, G; Dogné, JM; Innocenti, A; Masereel, B; Scozzafava, A; Supuran, CT; Vitale, RM | 1 |
| Brzozowski, Z; Innocenti, A; Supuran, CT; Sławiński, J | 1 |
| Chojnacki, J; Pogorzelska, A; Supuran, CT; Sławiński, J; Vullo, D; Żołnowska, B | 1 |
| Brożewicz, K; Pogorzelska, A; Supuran, CT; Sławiński, J; Vullo, D; Żołnowska, B | 1 |
| Beijersbergen, RL; Bernards, R; De Conti, G; Dos Santos Dias, M; Groot, K; Jochems, F; Leite de Oliveira, R; Lieftink, C; Morris, B; Mulero-Sánchez, A; Pogacar, Z; Roosen, M; Thijssen, B; Velds, A; Wardak, L | 1 |
| Abdel-Wahab, O; Bradley, RK; Cho, H; Chow, A; Chowell, D; Cui, D; De Neef, E; Diaz, LA; Durham, BH; Elhanati, Y; Erickson, C; Gabel, AM; Ghosh, A; Gigoux, M; Greenbaum, B; Hogg, SJ; Jin, J; Knorr, DA; Liu, J; Lu, B; Lu, SX; Merghoub, T; Molina, H; Rhodes, MC; Rousseau, B; Sabio, E; Shah, H; Shen, Y; Singer, M; Taylor, RE; Thomas, JD; Wang, E; Wolchok, JD; Xie, A; Zamarin, D | 1 |
| Berens, M; Clemons, PA; Dhruv, H; Kiefer, J; Kim, S; Mahendra, D; Schreiber, SL; Speyer, G; Tran, HJ | 1 |
| Capota, E; Gaskill, N; Goralski, M; Han, T; Kim, J; Nijhawan, D; Ting, TC; Williams, NS; Xie, Y | 1 |
| Cesur, H; Onyüksel, H; Pai, A; Rubinstein, I | 1 |
| Armand, JP; Beijnen, JH; Faivre, S; Fumoleau, P; Ravic, M; Raymond, E; Schellens, JH; Taïeb, J; ten Bokkel Huinink, WW; Wanders, J | 1 |
| Armand, JP; Beijnen, JH; Dittrich, Ch; Droz, JP; Dumez, H; Fumoleau, P; Mathôt, RA; Punt, C; Ravic, M; Raymond, E; Roché, H; Schellens, JH; Van Kesteren, Ch; Wanders, J | 1 |
| Beijnen, JH; Nan-Offeringa, L; Pluim, D; Ravic, M; Rosing, H; Schellens, JH; Schot, M; van sen Bongard, HJ | 1 |
| Beijnen, JH; Schellens, JH; Van Kesteren, C | 1 |
| Supuran, CT | 2 |
| Droz, JP; Faber, MN; Ravic, M; Roché, H; Schellens, JH; Terret, C; Wanders, J; Zanetta, S | 1 |
| Calvert, H; Dittrich, C; Dumez, H; Faber, M; Fumoleau, P; Hanauske, A; Ravic, M; Wanders, J; Yule, M | 1 |
| Blagden, S; de Bono, J | 1 |
| Beijnen, JH; Beumer, JH; Foley, K; Hillebrand, MJ; Pluim, D; Rosing, H; Schellens, JH; Yule, SM | 1 |
| Fujisaka, Y; Horiike, A; Nishioka, Y; Sakamoto, T; Shimoyama, T; Takayama, K; Tamura, T; Yamada, Y; Yamamoto, N; Yasuda, S | 1 |
| Dogné, JM; Masereel, B; Supuran, CT; Thiry, A | 1 |
| Dittrich, C; Gneist, M; Huitema, AD; King, AA; Wanders, J; Zandvliet, AS | 1 |
| Beijnen, JH; Copalu, W; Huitema, AD; Schellens, JH; Tamura, T; Yamada, Y; Zandvliet, AS | 1 |
| Campone, M; Faber, MN; Fumoleau, P; Punt, CJ; Ravic, M; van de Walle, B | 1 |
4 review(s) available for n-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide and Benign Neoplasms
| Article | Year |
|---|---|
E7070: a novel synthetic sulfonamide targeting the cell cycle progression for the treatment of cancer.
Topics: Antineoplastic Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; G1 Phase; Humans; Neoplasms; Sulfonamides; Treatment Outcome | 2002 |
Indisulam: an anticancer sulfonamide in clinical development.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Humans; Neoplasms; Sulfonamides; Technology, Pharmaceutical | 2003 |
Drugging cell cycle kinases in cancer therapy.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Binding Sites; Cyclin-Dependent Kinases; Flavonoids; Humans; Neoplasms; Oxazoles; Piperidines; Protein Kinase Inhibitors; Purines; Roscovitine; Staurosporine; Sulfonamides; Thiazoles | 2005 |
Development of small molecule carbonic anhydrase IX inhibitors.
Topics: Antigens, Neoplasm; Carbonic Anhydrase Inhibitors; Carbonic Anhydrase IX; Carbonic Anhydrases; Humans; Neoplasms; Sulfonamides | 2008 |
7 trial(s) available for n-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide and Benign Neoplasms
| Article | Year |
|---|---|
Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Agents; Drug Eruptions; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Metabolic Clearance Rate; Middle Aged; Neoplasms; Sulfonamides | 2002 |
Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG).
Topics: Adult; Antineoplastic Agents; Area Under Curve; Dose-Response Relationship, Drug; Fatigue; Female; Hematologic Diseases; Humans; Hypokalemia; Infusions, Intravenous; Kidney Diseases; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Platelet Count; Sulfonamides; Vomiting | 2003 |
Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Salvage Therapy; Sulfonamides | 2003 |
Human metabolism of [(14)C]indisulam following i.v. infusion in cancer patients.
Topics: Antineoplastic Agents; Biotransformation; Carbon Radioisotopes; Chemical Fractionation; Cholinesterase Inhibitors; Chromatography, High Pressure Liquid; Glucuronides; Humans; Infusions, Intravenous; Neoplasms; Spectrometry, Mass, Electrospray Ionization; Sulfonamides; Urine | 2005 |
Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days.
Topics: Adult; Aged; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Drug Administration Schedule; Female; Genotype; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Mixed Function Oxygenases; Neoplasms; Polymorphism, Genetic; Sulfonamides | 2005 |
A phase I and pharmacokinetic study of indisulam in combination with carboplatin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Sarcoma; Sulfonamides; Thrombocytopenia; Treatment Outcome | 2007 |
Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-early clinical studies group (ECSG).
Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Sulfonamides; Thrombocytopenia; Treatment Outcome | 2001 |
19 other study(ies) available for n-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide and Benign Neoplasms
| Article | Year |
|---|---|
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides derived from 4-isothiocyanato-benzolamide.
Topics: Benzolamide; Carbonic Anhydrase I; Carbonic Anhydrase II; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Cytosol; Humans; Neoplasms; Nerve Tissue Proteins; Sulfonamides | 2004 |
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating thioureido-sulfanilyl scaffolds.
Topics: Antigens, Neoplasm; Carbonic Anhydrase I; Carbonic Anhydrase II; Carbonic Anhydrase Inhibitors; Carbonic Anhydrase IX; Carbonic Anhydrases; Catalytic Domain; Cytosol; Humans; Kinetics; Neoplasms; Structure-Activity Relationship; Sulfonamides; Urea | 2005 |
Carbonic anhydrase inhibitors. Inhibition of the cytosolic human isozymes I and II, and the transmembrane, tumor-associated isozymes IX and XII with substituted aromatic sulfonamides activatable in hypoxic tumors.
Topics: Carbonic Anhydrase Inhibitors; Cell Hypoxia; Cell Membrane; Cytosol; Humans; Isoenzymes; Molecular Structure; Neoplasms; Sulfonamides; Water | 2006 |
Carbonic anhydrase inhibitors: Hypoxia-activatable sulfonamides incorporating disulfide bonds that target the tumor-associated isoform IX.
Topics: Antigens, Neoplasm; Carbonic Anhydrase II; Carbonic Anhydrase Inhibitors; Carbonic Anhydrase IX; Carbonic Anhydrases; Crystallography, X-Ray; Disulfides; Enzyme Activation; Humans; Hydrogen Bonding; Hypoxia; Isoenzymes; Models, Molecular; Molecular Structure; Neoplasms; Prodrugs; Protein Binding; Structure-Activity Relationship; Sulfhydryl Compounds; Sulfonamides | 2006 |
Carbonic anhydrase inhibitors: inhibition of cytosolic/tumor-associated isoforms I, II, and IX with iminodiacetic carboxylates/hydroxamates also incorporating benzenesulfonamide moieties.
Topics: Carbonic Anhydrase Inhibitors; Cell Membrane; Cytosol; Humans; Hydroxamic Acids; Indicators and Reagents; Isoenzymes; Neoplasms; Structure-Activity Relationship; Sulfonamides | 2007 |
Carbonic anhydrase inhibitors: inhibition of human cytosolic isozymes I and II and tumor-associated isozymes IX and XII with S-substituted 4-chloro-2-mercapto-5-methyl-benzenesulfonamides.
Topics: Benzenesulfonamides; Binding Sites; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Cytosol; Humans; Hydrocarbons, Chlorinated; Isoenzymes; Methylation; Models, Molecular; Molecular Sequence Data; Molecular Structure; Neoplasms; Protein Folding; Sequence Alignment; Structure-Activity Relationship; Sulfhydryl Compounds; Sulfonamides | 2008 |
Carbonic anhydrase inhibitors: bioreductive nitro-containing sulfonamides with selectivity for targeting the tumor associated isoforms IX and XII.
Topics: Amino Acid Sequence; Antigens, Neoplasm; Carbonic Anhydrase I; Carbonic Anhydrase II; Carbonic Anhydrase Inhibitors; Carbonic Anhydrase IX; Carbonic Anhydrases; Conserved Sequence; Crystallography, X-Ray; Humans; Isoenzymes; Models, Molecular; Molecular Sequence Data; Neoplasms; Nitro Compounds; Structure-Activity Relationship; Sulfonamides | 2008 |
Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII.
Topics: Antigens, Neoplasm; Carbonic Anhydrase I; Carbonic Anhydrase II; Carbonic Anhydrase Inhibitors; Carbonic Anhydrase IX; Carbonic Anhydrases; Cell Membrane; Cytosol; Humans; Isoenzymes; Neoplasms; Stereoisomerism; Substrate Specificity; Sulfonamides | 2010 |
Carbonic anhydrase inhibitors. Synthesis, and molecular structure of novel series N-substituted N'-(2-arylmethylthio-4-chloro-5-methylbenzenesulfonyl)guanidines and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associat
Topics: Antigens, Neoplasm; Antineoplastic Agents; Carbonic Anhydrase I; Carbonic Anhydrase II; Carbonic Anhydrase Inhibitors; Carbonic Anhydrase IX; Carbonic Anhydrases; Cell Line, Tumor; Cytosol; Guanidines; Humans; Isoenzymes; Models, Molecular; Neoplasms; Structure-Activity Relationship | 2014 |
Carbonic anhydrase inhibitors. Synthesis of a novel series of 5-substituted 2,4-dichlorobenzenesulfonamides and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII.
Topics: Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Cell Membrane; Dose-Response Relationship, Drug; Humans; Isoenzymes; Molecular Structure; Neoplasms; Structure-Activity Relationship; Sulfonamides | 2014 |
Genetic and compound screens uncover factors modulating cancer cell response to indisulam.
Topics: Antineoplastic Agents; Intracellular Signaling Peptides and Proteins; Neoplasms; RNA Splicing Factors; Sulfonamides | 2022 |
Pharmacologic modulation of RNA splicing enhances anti-tumor immunity.
Topics: Animals; Antigen Presentation; Antigens, Neoplasm; Cell Line, Tumor; Cell Proliferation; Epitopes; Ethylenediamines; Gene Expression Regulation, Neoplastic; Hematopoiesis; Histocompatibility Antigens Class I; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Inflammation; Mice, Inbred C57BL; Neoplasms; Peptides; Protein Isoforms; Pyrroles; RNA Splicing; Sulfonamides; T-Lymphocytes | 2021 |
DIFFERENTIAL PATHWAY DEPENDENCY DISCOVERY ASSOCIATED WITH DRUG RESPONSE ACROSS CANCER CELL LINES.
Topics: Algorithms; Cell Line, Tumor; Computational Biology; Death-Associated Protein Kinases; Drug Screening Assays, Antitumor; Gene Expression Profiling; Gene Regulatory Networks; High-Throughput Screening Assays; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Neoplasms; Precision Medicine; Protein Kinase Inhibitors; Pyrrolidines; Signal Transduction; Sulfonamides | 2017 |
Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15.
Topics: Amino Acid Substitution; Animals; Antineoplastic Agents; Biomarkers, Pharmacological; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Mice; Mice, Knockout; Molecular Targeted Therapy; Mutation; Neoplasms; Nuclear Proteins; Proteasome Endopeptidase Complex; Proteolysis; RNA Splicing; RNA-Binding Proteins; Sulfonamides; Ubiquitin-Protein Ligase Complexes; Ubiquitination; Xenograft Model Antitumor Assays | 2017 |
Self-associated indisulam in phospholipid-based nanomicelles: a potential nanomedicine for cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Micelles; Nanomedicine; Nanoparticles; Neoplasms; Particle Size; Phospholipids; Solubility; Sulfonamides | 2009 |
Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation.
Topics: Antineoplastic Agents; Clinical Trials, Phase I as Topic; Humans; Models, Theoretical; Neoplasms; Sulfonamides | 2002 |
An excretion balance and pharmacokinetic study of the novel anticancer agent E7070 in cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Male; Middle Aged; Neoplasms; Prospective Studies; Sulfonamides | 2002 |
Targeting tumor-associated carbonic anhydrase IX in cancer therapy.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Carbonic Anhydrase Inhibitors; Carbonic Anhydrase IX; Carbonic Anhydrases; Catalytic Domain; Drug Delivery Systems; Drug Resistance, Neoplasm; Humans; Hydrogen-Ion Concentration; Hypoxia; Neoplasms; Protein Conformation; Sulfonamides | 2006 |
CYP2C9 and CYP2C19 polymorphic forms are related to increased indisulam exposure and higher risk of severe hematologic toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Female; Genome, Human; Humans; Liver; Male; Middle Aged; Mixed Function Oxygenases; Neoplasms; Polymorphism, Genetic; Risk; Sulfonamides | 2007 |